Dr. Reddy's Laboratories (RDY) Competitors $14.00 -0.03 (-0.21%) Closing price 10/8/2025 03:59 PM EasternExtended Trading$14.00 0.00 (0.00%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RDY vs. TAK, ARGX, ONC, INSM, BNTX, TEVA, GMAB, SMMT, ASND, and VTRSShould you be buying Dr. Reddy's Laboratories stock or one of its competitors? The main competitors of Dr. Reddy's Laboratories include Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), Insmed (INSM), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Ascendis Pharma A/S (ASND), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry. Dr. Reddy's Laboratories vs. Its Competitors Takeda Pharmaceutical argenex BeOne Medicines Insmed BioNTech Teva Pharmaceutical Industries Genmab A/S Summit Therapeutics Ascendis Pharma A/S Viatris Dr. Reddy's Laboratories (NYSE:RDY) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership. Which has more volatility and risk, RDY or TAK? Dr. Reddy's Laboratories has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500. Which has stronger earnings & valuation, RDY or TAK? Takeda Pharmaceutical has lower revenue, but higher earnings than Dr. Reddy's Laboratories. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDr. Reddy's Laboratories$334.26B0.03$663M$0.6621.21Takeda Pharmaceutical$30.09B1.51$712.33M$0.3047.73 Do analysts rate RDY or TAK? Dr. Reddy's Laboratories presently has a consensus price target of $16.95, suggesting a potential upside of 21.07%. Given Dr. Reddy's Laboratories' stronger consensus rating and higher possible upside, research analysts plainly believe Dr. Reddy's Laboratories is more favorable than Takeda Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.83Takeda Pharmaceutical 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is RDY or TAK a better dividend stock? Dr. Reddy's Laboratories pays an annual dividend of $0.07 per share and has a dividend yield of 0.5%. Takeda Pharmaceutical pays an annual dividend of $0.55 per share and has a dividend yield of 3.8%. Dr. Reddy's Laboratories pays out 10.6% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 183.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Do insiders and institutionals hold more shares of RDY or TAK? 3.8% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is RDY or TAK more profitable? Dr. Reddy's Laboratories has a net margin of 16.99% compared to Takeda Pharmaceutical's net margin of 3.20%. Dr. Reddy's Laboratories' return on equity of 17.25% beat Takeda Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Dr. Reddy's Laboratories16.99% 17.25% 11.63% Takeda Pharmaceutical 3.20%10.50%5.10% Does the media prefer RDY or TAK? In the previous week, Takeda Pharmaceutical had 1 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 4 mentions for Takeda Pharmaceutical and 3 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 1.62 beat Takeda Pharmaceutical's score of 0.24 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Takeda Pharmaceutical 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryDr. Reddy's Laboratories beats Takeda Pharmaceutical on 13 of the 19 factors compared between the two stocks. Get Dr. Reddy's Laboratories News Delivered to You Automatically Sign up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RDY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RDY vs. The Competition Export to ExcelMetricDr. Reddy's LaboratoriesMED IndustryMedical SectorNYSE ExchangeMarket Cap$11.71B$4.47B$6.10B$22.02BDividend Yield0.51%0.90%5.69%3.59%P/E Ratio21.2110.7985.6029.86Price / Sales0.0322.36538.2165.92Price / Cash13.597.0637.9224.43Price / Book2.964.2913.244.64Net Income$663M-$134.23M$3.30B$1.01B7 Day Performance-0.53%5.82%4.35%0.44%1 Month Performance-4.18%12.05%9.51%3.13%1 Year Performance-11.14%71.33%88.04%15.30% Dr. Reddy's Laboratories Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RDYDr. Reddy's Laboratories3.2752 of 5 stars$14.00-0.2%$16.95+21.1%-11.1%$11.71B$334.26B21.2127,811News CoveragePositive NewsAnalyst ForecastTAKTakeda Pharmaceutical2.4314 of 5 stars$14.60-1.0%N/A+0.2%$46.90B$30.09B48.6547,455ARGXargenex3.6639 of 5 stars$719.04+1.0%$789.20+9.8%+51.6%$43.55B$2.25B36.871,599Analyst ForecastONCBeOne Medicines1.469 of 5 stars$332.83+2.1%$336.30+1.0%N/A$35.74B$3.81B-192.3911,000Analyst ForecastINSMInsmed3.2682 of 5 stars$141.65+3.4%$139.86-1.3%+126.7%$28.96B$363.71M-24.811,271Analyst ForecastBNTXBioNTech2.651 of 5 stars$98.10+0.0%$134.56+37.2%-11.7%$23.58B$2.98B-61.316,772Positive NewsTEVATeva Pharmaceutical Industries3.0112 of 5 stars$19.17+4.5%$25.14+31.2%+15.3%$21.04B$16.54B-119.8136,830Analyst ForecastAnalyst RevisionGMABGenmab A/S4.3435 of 5 stars$29.33+0.9%$40.00+36.4%+38.8%$18.65B$3.12B14.742,682Analyst ForecastHigh Trading VolumeSMMTSummit Therapeutics3.1722 of 5 stars$21.16+1.0%$31.29+47.9%+18.5%$15.56B$700K-20.95110Analyst ForecastASNDAscendis Pharma A/S3.0175 of 5 stars$191.60-0.2%$244.36+27.5%+59.1%$11.83B$393.54M-37.131,017News CoverageAnalyst ForecastVTRSViatris1.678 of 5 stars$9.62+1.1%$10.40+8.1%-11.9%$11.10B$14.74B-3.3232,000Analyst Forecast Related Companies and Tools Related Companies Takeda Pharmaceutical Alternatives argenex Alternatives BeOne Medicines Alternatives Insmed Alternatives BioNTech Alternatives Teva Pharmaceutical Industries Alternatives Genmab A/S Alternatives Summit Therapeutics Alternatives Ascendis Pharma A/S Alternatives Viatris Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:RDY) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dr. Reddy's Laboratories Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Dr. Reddy's Laboratories With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
